Survodutide

Buy Survodutide Online

Survodutide is a once-weekly dual glucagon and GLP-1 receptor agonist being investigated for obesity, metabolic disease, and metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials have reported substantial body-weight reductions alongside metabolic and liver-related improvements.

Product Information

Survodutide activates both GLP-1 and glucagon receptors. Phase 2 research has evaluated it in adults with obesity and in people with MASH and liver fibrosis, with studies examining body weight, liver fat, fibrosis, glucose regulation, and other metabolic markers.

How It Works

GLP-1 receptor activation influences appetite and glucose regulation, while glucagon receptor activation affects energy metabolism and lipid handling. Survodutide combines these two signals into a single dual-action molecule.

Potential Benefits

1. Weight-Management Research

Phase 2 obesity research has demonstrated dose-dependent reductions in body weight with once-weekly survodutide. The strongest studied doses produced substantial average weight reductions over the treatment period.

2. Appetite Regulation

The GLP-1 component can reduce appetite and influence food intake, supporting the investigation of survodutide as a weight-management therapy.

3. Metabolic Support

Survodutide has been studied for effects on glucose-related and other metabolic biomarkers. Research has reported improvements in several measures related to metabolic function.

4. Liver Health Research

Survodutide has also been investigated in people with MASH and liver fibrosis. Phase 2 research has examined histological improvement, liver fat reduction, and changes in fibrosis.

Dosage

In a phase 2 obesity trial, survodutide was studied at once-weekly doses of 0.6, 2.4, 3.6, and 4.8 mg, using a dose-escalation and maintenance design over 46 weeks. These were research doses and should not be treated as individualized dosing instructions.

Side Effects

Gastrointestinal adverse effects are the most frequently reported issues in clinical research, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In the phase 2 obesity trial, gastrointestinal events were more common with survodutide than placebo.

References

1. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology. 2024;12(3):162-173. PMID: 38330987. PubMed
2. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 2024. PMID: 38847460. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.